Management of metabolic-associated fatty liver disease: The diabetology perspective

Table 1 Management of metabolic-associated fatty liver disease directed against the risk factors

No	Disease/condition	Directed therapy	Supportive therapies
1	Overweight and obesity	Anti-obesity drugs, Bariatric surgery, lifestyle intervention (Calorie-restriction, dietary pattern, etc.)	MAFLD: Newer agents targeting on cellular inflammation and oxidative stress.
2	T2DM	Hypoglycemic agents like Metformin, GLP-1RAs, SGLT-2i, Thiazolidinediones and DPP-4 inhibitors	Fibrotic MAFLD: Potential future anti-fibrotic agents.
3	> 2 metabolic risks	Modulators of metabolism (Farnesoid X receptor agonsit, Peroxisome proliferator-activated receptor, fibroblast growth receptors, statins, aspirin)	Cirrhosis Complications: Control portal hypertension and bacterial peritonitis prophylaxis. End-stage liver diseases: Liver transplantation.

T2DM: Type 2 diabetes mellitus; GLP-1RA: Glucagon-like insulinotropic peptide-1 receptor agonist; SGLT-2i: Sodium glucose cotransporter-2 inhibitors; DPP-4: Dipeptidyl peptidase-4; MAFLD: Metabolic-associated fatty live disease.